

2nd MEDITERRANEAN FORUM OF HEPATITIS AND GERD



STEIGENBERGER | LUXOR
NILE PALACE

FEBRUARY 7-10, 2018



IN COLLABORATION WITH

**THE UPPER EGYPT SOCIETY
OF HEPATO-GASTROENTEROLOGY
AND ENDOSCOPY**



ORGANIZED BY

**THE EGYPTIAN SOCIETY OF
HEPATOLOGY, GASTROENTEROLOGY
& INFECTIOUS DISEASES IN ALEXANDRIA**



Mediterranean forum of Hepatitis and GERD is a unique update meeting for three topics only allowing experts to present cutting edge knowledge about updates.

On behalf of ESHGID we invite all experts and interested doctors to participate in the 2nd Mediterranean Forum of Hepatitis and GERD that will be held in Luxor, February 7-9, 2018, to discuss Hepatitis and GERD updates as well as HCC in the era of DAAs.

Sessions will be specialized and much updated discussing the most important topics in hepatitis and gastro esophageal reflux disease.

All participants are encouraged to interact with expertise. Also young doctors and investigators are welcomed to participate and present short update lectures in each session provided that they will send suggestions very soon. We specified special session for poster presentations that will be discussed and guided by eminent experts.



BOARD OF ESHGID

President

Prof. Helmy Abaza

Treasurer

Prof. Siham Abdel-Rehim

Members

Prof. Abdel-Fattah Hanno

Prof. Ahmed Shawki

Prof. Ahmed Zaid

Prof. Alaa Abdo

Prof. Amany El-Yamany

Prof. El-Saeed Ibrahim

Secretary General

Prof. Yousry Taher

Vice President

Prof. Mostafa EL-Hennawy

Prof. Farouk Mekky

Prof. Fatahllah Sedki

Prof. Hassan El-Bahrawy

Prof. Khaled Mohie

Prof. Mohamed Kassem



TOPICS OF 1ST DAY

HEPATITIS

UPDATES

SESSION 1

- Early treatment HCV prevent HCC.
- Screening for HCV among Egyptian population, is there any news?
- Relapse after DAAs treatment highlights in the era of new DAAs.
- Debrief of AASLD 2017.

SESSION 2

- Treatment of advanced HCV liver is still a difficult problem, what is new?
- Available and new drugs, what about the future of relapses and mutations?
- DAAs and HCC last data from AASLD.

SESSION 3

- HBV news in the near future.
- Nucleotides (Sides) are still drugs of choice for HBV treatment.
- HBV and HCC impact of treatment.

SESSION 4

- Primary biliary cholangitis, P Sclerosing cholangitis and IBD, what is new?
- Primary biliary cholangitis diagnosis and update management.
- P Sclerosing cholangitis and IBD, What is new?
- Microbiota and IBD recent advances.



TOPICS OF 2ND DAY

GERD

UPDATES

SESSION 1

- Extreme gastro esophageal reflux disease management.
- Laryngopharyngeal reflux disease, case presentation.
- New era of PPI / double release double action.

SESSION 2

- GERD and obesity.
- Surgery in GERD management for obese and non-obese.
- Dual release PPI, solved the problem of erosive esophagitis.
- PPIs and Portal hypertension.

SESSION 3

- New aspects of GERD pathogenesis.
- Immediate release PPI, its impact in GERD management.
- Delayed release PPIs are still leading the market.
- Helicobacter pylori and MALT lymphoma.

SESSION 4

- HCC role of biomarkers in targeted therapy.
- TACE for advanced HCC.
- Pitfalls in loco regional HCC treatment.
- Hepatic resection for non HCC focal Hepatic lesion.



TOPICS OF 3RD DAY

POSTER PRESENTATIONS



CONGRESS PACKAGE

REGISTRATION

Egyptians ➤ 800 L.E

Expatriates ➤ 300 \$

ACCOMMODATION PACKAGE 3 NIGHTS (Full Board)

Sgl. Room ➤➤ Egyptians ➤ 4700 L.E Expatriates ➤ 900 \$

Dbl. Room ➤➤ Egyptians ➤ 5600 L.E Expatriates ➤ 1050 \$

Tpl. Room ➤➤ Egyptians ➤ 6500 L.E Expatriates ➤ 1200 \$

Official Organizer of the Congress: **ALFA MEDICAL**



53 El-Makrizy Street, Roxy, Doctors Tower, Cairo, Egypt

Tel. : +20 (2) 24532 916/17 - Fax: +20 (2) 24 533 515

Mob. : +20 (10) 222 40 574 / +20 (10) 222 40 575

Email : info@alfamedical.org / alfa@alfamedical.org

WWW.ALFAMEDICAL.ORG